Evidence map›Paper›PMID 34526307›Full record

Trial reportBMJ (Clinical research ed.)2021

Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial.

Christopher E Ramsden, Daisy Zamora, Keturah R Faurot, Beth MacIntosh, Mark Horowitz, Gregory S Keyes, Zhi-Xin Yuan, Vanessa Miller, Chanee Lynch, Gilson Honvoh and 14 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ (Clinical research ed.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02012790 (Clinical & Metabolic Effects of Altering n-3 & n-6 Fatty Acids in Migraine), which is not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02012790 nacompletednot on this map

Clinical & Metabolic Effects of Altering n-3 & n-6 Fatty Acids in Migraine (RCT)

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2014 to 2018Enrolled182ConditionsMigraine DisordersArmsDiet
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Hallmarks of primary headache: part 1 - migraine.The journal of headache and pain · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Christopher E RamsdenLipid Peroxidation Unit, Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA chris.ramsden@nih.gov.ORCID 0000-0002-4058-7630
Daisy ZamoraLipid Peroxidation Unit, Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.
Keturah R FaurotDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Beth MacIntoshDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mark HorowitzLipid Peroxidation Unit, Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.
Gregory S KeyesLipid Peroxidation Unit, Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.
Zhi-Xin YuanLipid Peroxidation Unit, Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.
Vanessa MillerDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chanee LynchDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gilson HonvohDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jinyoung ParkDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Russell LevyCytokine Analysis Core, UNC Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Anthony F DomenichielloLipid Peroxidation Unit, Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.
Angela JohnstonDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sharon Majchrzak-HongIntramural Program of the National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA.
Joseph R HibbelnIntramural Program of the National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA.
David A BarrowCytokine Analysis Core, UNC Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
James LoewkeIntramural Program of the National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA.
John M DavisDepartment of Psychiatry, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Andrew MannesDepartment of Perioperative Medicine, NIH Clinical Center, Bethesda, MD, USA.
Olafur S PalssonDepartment of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chirayath M SuchindranDepartment of Biostatistics, Gillings School of Global Public Health, Chapel Hill, NC, USA.
Susan A GaylordDepartment of Physical Medicine and Rehabilitation, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
J Douglas MannDepartment of Neurology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
University of North Carolina at Chapel Hill · USNational Institute on Aging · USNational Institute on Alcohol Abuse and Alcoholism · USNational Institutes of Health Clinical Center · US

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Venkata Saroja Voruganti · 1999 to 2026
$31.6M
UNC Research Fellowship in Complementary and Alternative MedicineT32AT003378 · NCCIH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Keturah Ruth Faurot, Susan Gaylord · 2007 to 2026
$7.8M
Clinical & metabolic effects of altering n-3 & n-6 fatty acids in migraine (RCT)R01AT007813 · NCCIH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MANN, JOHN DOUGLAS · 2013 to 2017
$3.5M
NCATS NIH HHS UL1 TR002489NCCIH NIH HHS R01 AT007813NCCIH NIH HHS T32 AT003378NIDDK NIH HHS P30 DK056350
6 · The paper itself

Abstract

objectiveTo determine whether dietary interventions that increase n-3 fatty acids with and without reduction in n-6 linoleic acid can alter circulating lipid mediators implicated in headache pathogenesis, and decrease headache in adults with migraine.

designThree arm, parallel group, randomized, modified double blind, controlled trial.

settingAmbulatory, academic medical center in the United States over 16 weeks.

participants182 participants (88% women, mean age 38 years) with migraines on 5-20 days per month (67% met criteria for chronic migraine).

interventionsThree diets designed with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and linoleic acid altered as controlled variables: H3 diet (n=61)-increase EPA+DHA to 1.5 g/day and maintain linoleic acid at around 7% of energy; H3-L6 diet (n=61)-increase n-3 EPA+DHA to 1.5 g/day and decrease linoleic acid to ≤1.8% of energy; control diet (n=60)-maintain EPA+DHA at <150 mg/day and linoleic acid at around 7% of energy. All participants received foods accounting for two thirds of daily food energy and continued usual care.

main outcome measuresThe primary endpoints (week 16) were the antinociceptive mediator 17-hydroxydocosahexaenoic acid (17-HDHA) in blood and the headache impact test (HIT-6), a six item questionnaire assessing headache impact on quality of life. Headache frequency was assessed daily with an electronic diary.

resultsIn intention-to-treat analyses (n=182), the H3-L6 and H3 diets increased circulating 17-HDHA (log ng/mL) compared with the control diet (baseline-adjusted mean difference 0.6, 95% confidence interval 0.2 to 0.9; 0.7, 0.4 to 1.1, respectively). The observed improvement in HIT-6 scores in the H3-L6 and H3 groups was not statistically significant (-1.6, -4.2 to 1.0, and -1.5, -4.2 to 1.2, respectively). Compared with the control diet, the H3-L6 and H3 diets decreased total headache hours per day (-1.7, -2.5 to -0.9, and -1.3, -2.1 to -0.5, respectively), moderate to severe headache hours per day (-0.8, -1.2 to -0.4, and -0.7, -1.1 to -0.3, respectively), and headache days per month (-4.0, -5.2 to -2.7, and -2.0, -3.3 to -0.7, respectively). The H3-L6 diet decreased headache days per month more than the H3 diet (-2.0, -3.2 to -0.8), suggesting additional benefit from lowering dietary linoleic acid. The H3-L6 and H3 diets altered n-3 and n-6 fatty acids and several of their nociceptive oxylipin derivatives in plasma, serum, erythrocytes or immune cells, but did not alter classic headache mediators calcitonin gene related peptide and prostaglandin E2.

conclusionsThe H3-L6 and H3 interventions altered bioactive mediators implicated in headache pathogenesis and decreased frequency and severity of headaches, but did not significantly improve quality of life.

trial registrationClinicalTrials.gov NCT02012790.

Indexed as

AdultDocosahexaenoic AcidsDouble-Blind MethodFatty Acids, Omega-3Fatty Acids, Omega-6FemaleHumansMaleMiddle AgedMigraine DisordersNociceptionSelf ReportSeverity of Illness Index17-hydroxy-4,7,10,13,15,19-docosahexaenoic acidDocosahexaenoic AcidsFatty Acids, Omega-3Fatty Acids, Omega-6

Identifiers

PMID34526307
PMCPMC8244542
OpenAlexW3173225581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.